HEARTCARE-B (06609) announced that the registration application for its self-expanding intracranial drug-eluting stent, developed by the Group, has been accepted by China's National Medical Products Administration (NMPA). This self-expanding intracranial drug-eluting stent is intended for the treatment of intracranial atherosclerotic stenosis, providing support and opening for narrowed and obstructed lumens, while effectively preventing in-stent restenosis. According to publicly available information, there are currently no similar products approved for market launch globally, and the company's research and development progress for this type of product is at a leading level within the industry.